Competitive Landscape Assessment In The Rheumatoid Arthritis Space
- An EU based large pharma client intended to evaluate competitive landscape to support the market entry strategy for its in-house late stage RA product
- Also study key competitor assets in the rheumatology domain & their updates in EULAR and ACR conference
- To track of competitive activity for client in the RA (Rheumatoid Arthritis) domain. This supported client's R&D team to strategize internal
- We took three-pronged approach for this project:
- – In-depth competitive monitoring to identify the high priority threats which involved identifying the comprehensive asset list through Citeline Pharma projects and other databases
- – Tracking updates of each competitor asset through varied subscribed and public sources – monitoring key events through investor presentation and earning calls analysis
- – Monitoring the efficacy/safety analysis of key competitors through published results online and through on-site conference intelligence
- The exercise helped in identifying product strategy of key competitor companies in RA space
- Conference coverage in the rheumatology therapy area enabled the client with key scientific insights on competitor assets. This supported client's R&D team to strategize development approach of their assets
